1. |
Dalmau J, Graus F. Antibody-Mediated Encephalitis. N Engl J Med, 2018, 378(9): 840-851.
|
2. |
Spatola M, Dalmau J. Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. Curr Opin Neurol, 2017, 30(3): 345-353.
|
3. |
Mihailović LT, Cupić D. Epileptiform activity evoked by intracerebral injection of anti-brain antibodies. Brain Res, 1971, 32(1): 97-124.
|
4. |
Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics, 1996, 97(3): 375-379.
|
5. |
Ong MS, Kohane IS, Cai T, et al. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol, 2014, 71(5): 569-574.
|
6. |
Emsley HC, Appleton RE, Whitmore CL, et al. Variations in inflammation-related genes may be associated with childhood febrile seizure susceptibility. Seizure, 2014, 23(6): 457-461.
|
7. |
Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 2014, 55(4): 475-482.
|
8. |
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(4): 512-521.
|
9. |
Geis C, Planagumà J, Carreño M, et al. Autoimmune seizures and epilepsy. J Clin Invest, 2019, 129(3): 926-940.
|
10. |
Vezzani A, Dingledine R, Rossetti AO. Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Rev Neurother, 2015, 15(9): 1081-1092.
|
11. |
van Vliet EA, Aronica E, Vezzani A, et al. Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies. Neuropathol Appl Neurobiol, 2018, 44(1): 91-111.
|
12. |
Viaccoz A, Desestret V, Ducray F, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology, 2014, 82(7): 556-563.
|
13. |
Titulaer MJ, Dalmau J. Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men. Neurology, 2014, 82(7): 550-551.
|
14. |
Liu X, Yan B, Wang R, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study. Epilepsia, 2017, 58(12): 2104-2111.
|
15. |
Huang Q, Ma M, Wei X, et al. Characteristics of seizure and antiepileptic drug utilization in outpatients with autoimmune encephalitis. Front Neurol, 2018, 9: 1136.
|
16. |
Armangue T, Petit-Pedrol M, Dalmau J. Autoimmune encephalitis in children. J Child Neurol, 2012, 27(11): 1460-1469.
|
17. |
Sai Y, Zhang X, Feng M,, et al. Clinical diagnosis and treatment of pediatric anti-N-methyl-D-aspartate receptor encephalitis: A single center retrospective study. Exp Ther Med, 2018, 16(2): 1442-1448.
|
18. |
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol, 2013, 12(2): 157-165.
|
19. |
Miya K, Takahashi Y, Mori H. Anti-NMDAR autoimmune encephalitis. Brain Dev, 2014, 36(8): 645-652.
|
20. |
Ramanathan S, Mohammad SS, Brilot F, et al. Autoimmune encephalitis: recent updates and emerging challenges. J Clin Neurosci, 2014, 21(5): 722-730.
|
21. |
Huang Q, Wu Y, Qin R, et al. Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis. J Neurol, 2016, 263(12): 2446-2455.
|
22. |
Zekeridou A, Karantoni E, Viaccoz A, et al. Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis. J Neurol, 2015, 262(8): 1859-1866.
|
23. |
Feyissa AM, Lòpez CAS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm, 2017, 4(4): e353.
|
24. |
张梅娟, 管得宁, 王晓云, 等. 面臂肌张力障碍型癫痫的临床特征以及预后. 中国神经免疫学和神经病学杂志, 2018, 25(06): 443-446.
|
25. |
Navarro V, Kas A, Apartis E, et al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain, 2016, 139(Pt 4): 1079-1093.
|
26. |
Malter MP, Frisch C, Schoene-Bake JC, et al. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol, 2014, 261(9): 1695-705.
|
27. |
van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology, 2016, 87(14): 1449-1456.
|
28. |
Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol, 2014, 13(3): 276-286.
|
29. |
Spatola M, Petit-Pedrol M, Simabukuro MM, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology, 2017, 88(11): 1012-1020.
|
30. |
Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol, 2010, 9(1): 67-76.
|
31. |
Chen X, Liu F, Li JM, et al. Encephalitis with antibodies against the GABAB receptor: seizures as the most common presentation at admission. Neurol Res, 2017, 39(11): 973-980.
|
32. |
Cui J, Bu H, He J, et al. The gamma-aminobutyric acid-B receptor (GABAB) encephalitis: clinical manifestations and response to immunotherapy. Int J Neurosci, 2018, 128(7): 627-633.
|
33. |
Di PF, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol, 2011, 138(3): 2472-54.
|
34. |
Hino-Fukuyo N, Haginoya K, Nakashima I, et al. Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies. Brain Dev, 2015, 37(9): 849-852.
|
35. |
Rossor T, Benetou C, Wright S, et al. Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. Mult Scler, 2019: 1352458518823486.
|
36. |
Shavit YB, Graus F, Probst A, et al. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol, 1999, 45(2): 255-258.
|
37. |
Bernal F, Graus F, Pifarré A, et al. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol, 2002, 103(5): 509-515.
|
38. |
Veri K, Uibo O, Talvik T, et al. Newly-diagnosed pediatric epilepsy is associated with elevated autoantibodies to glutamic acid decarboxylase but not cardiolipin. Epilepsy Res, 2013, 105(1-2): 86-91.
|
39. |
Liimatainen S, Peltola M, Sabater L, et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia, 2010, 51(5): 760-767.
|
40. |
Daif A, Lukas RV, Issa NP, et al. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav, 2018, 80: 331-336.
|
41. |
Malter MP, Frisch C, Zeitler H, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure, 2015, 30: 57-63.
|
42. |
Castellano JF, Meyer JA, Lado FA. A Case Series of Adult-Onset Rasmussen's Encephalitis: Diagnostic and Therapeutic Challenges. Front Neurol, 2017, 8: 564.
|
43. |
Yeshokumar AK, Pardo CA. Autoimmune Epilepsies. Semin Pediatr Neurol, 2017, 24(3): 161-167.
|
44. |
Bien CG, Schramm J. Treatment of Rasmussen encephalitis half a century after its initial description: promising prospects and a dilemma. Epilepsy Res, 2009, 86(2-3): 101-112.
|
45. |
董军, 张鹏, 陈阳美. 新发难治性癫痫持续状态研究进展. 癫痫杂志, 2019, 5(01): 30-33.
|
46. |
Meletti S, Giovannini G, d'Orsi G, et al. New-Onset Refractory Status Epilepticus with Claustrum Damage: Definition of the Clinical and Neuroimaging Features. Front Neurol, 2017, 8: 111.
|